ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : immune suppression
Scheme : Project Grants
Clear All
Filter by Field of Research
Cellular Immunology (16)
Cancer Cell Biology (7)
Medical Virology (7)
Immunology not elsewhere classified (6)
Paediatrics (5)
Tumour Immunology (5)
Biochemistry and Cell Biology not elsewhere classified (4)
Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (4)
Medical Bacteriology (4)
Medical Parasitology (4)
Allergy (3)
Autoimmunity (3)
Humoural Immunology and Immunochemistry (3)
Respiratory Diseases (3)
Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies) (2)
Cell Development, Proliferation and Death (2)
Haematological Tumours (2)
Haematology (2)
Infectious Diseases (2)
Innate Immunity (2)
Medical and Health Sciences not elsewhere classified (2)
Paediatrics and Reproductive Medicine not elsewhere classified (2)
Preventive Medicine (2)
Structural Biology (incl. Macromolecular Modelling) (2)
Aboriginal and Torres Strait Islander Health (1)
Anaesthesiology (1)
Cardiology (incl. Cardiovascular Diseases) (1)
Central Nervous System (1)
Clinical Sciences not elsewhere classified (1)
Enzymes (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (117)
Filter by Status
Closed (117)
Filter by Scheme
Project Grants (117)
Filter by Country
Australia (15)
Filter by Australian State/Territory
VIC (10)
ACT (4)
SA (2)
QLD (1)
  • Researchers (0)
  • Funded Activities (117)
  • Organisations (52)
  • Funded Activity

    The Role Of Cytokines In Tumor-induced Immunosuppression

    Funder
    National Health and Medical Research Council
    Funding Amount
    $754,473.00
    Summary
    Cancer-induced immune suppression is a major obstacle to the effective treatment of many cancers. We have shown that the cytokine IL-23, plays an important role in cancer initiation, growth and development. My project aims to characterize the cells that produce IL-23 in the cancer microenvironment and define how it suppresses cells of the immune system. A greater understanding of this cytokine’s mechanism of action will enable the rational improvement of treatments for patients with cancer
    More information
    Funded Activity

    Attenuating Severe Infections In Chronic Inflammatory Diseases Through Modulation Of Transforming Growth Factor-β Activity

    Funder
    National Health and Medical Research Council
    Funding Amount
    $611,793.00
    Summary
    Asthma and chronic obstructive pulmonary disease (COPD) are characterised by enhanced TGF? expression, which is accompanied by susceptibility to recurrent viral and bacterial infections. Such infections exacerbate lung inflammation in these patients, generally requiring emergency department treatment. This project proposes to clarify the therapeutic potential of TGF? inhibitors to reduce the impact of viral infections in patients with COPD and asthma.
    More information
    Funded Activity

    Understanding The Mechanisms Of Respiratory Viral Infection- And COPD-induced Predisposition To Secondary Bacterial Pneumonia

    Funder
    National Health and Medical Research Council
    Funding Amount
    $593,888.00
    Summary
    Bacterial pneumonia is a major health problem particularly for children and the elderly. Bacteria are resistant to antibiotics and new treatments are urgently required. Viral infection and emphysema lead to increased risk of pneumonia. We will investigate the mechanisms of how viral infections and emphysema lead to pneumonia. We will then use new treatments to stop these mechanisms from occurring to prevent and treat pneumonia. This project may produce new treatments and cures for pneumonia.
    More information
    Funded Activity

    Cross Presentation And Tumour Immunology

    Funder
    National Health and Medical Research Council
    Funding Amount
    $445,093.00
    Summary
    Cancers have thousands of mutations, so they should look a bit like a viral infection. If so, why doesn’t the immune system just destroy them outright, like they would a virus? We think the mutated proteins cause a ‘brake’ to be put on the anti-cancer immune response, and also that cancers subvert the anti-cancer attack by remaining hidden in the target zone. Unblocking these “brakes” might lead to new treatments.
    More information
    Funded Activity

    Tumour Induced Innate Immune Responses That Control Breast Cancer Metastases

    Funder
    National Health and Medical Research Council
    Funding Amount
    $596,164.00
    Summary
    The mechanisms of breast cancer spread to bone are largely unknown. We have found that cross-talk between tumour cells and the immune system exists to induce anti-tumour immune responses. By decreasing the release of proteins known to activate immune responses (type I interferons), tumour cells can hide from such responses and spread to tissues such as bone. We aim to identify the immune responses activated by type I IFN and if restoration of these pathways can block breast cancer spread to bone .... The mechanisms of breast cancer spread to bone are largely unknown. We have found that cross-talk between tumour cells and the immune system exists to induce anti-tumour immune responses. By decreasing the release of proteins known to activate immune responses (type I interferons), tumour cells can hide from such responses and spread to tissues such as bone. We aim to identify the immune responses activated by type I IFN and if restoration of these pathways can block breast cancer spread to bone.
    Read more Read less
    More information
    Funded Activity

    Using Mouse Models To Decipher The Function Of Caspase-2 In Limiting Aneuploidy Tolerance And Cancer

    Funder
    National Health and Medical Research Council
    Funding Amount
    $871,162.00
    Summary
    Aneuploidy or abnormal chromosome number is a feature of cancer cells. The extent of aneuploidy is often predictive of prognosis and the effectiveness of cancer treatment. We discovered that a tumour suppressing protein, caspase-2, is important for deleting aneuploid cells that may otherwise become cancerous. In this project we will use cancer models to decipher how caspase-2 safeguards against aneuploidy and cancer to better understand how cancer cells can survive and be targeted for treatment.
    More information
    Funded Activity

    ‘Transcriptional Tumour Suppression’ By Pax5 And Ikaros In B Progenitor Acute Lymphoblastic Leukaemia

    Funder
    National Health and Medical Research Council
    Funding Amount
    $558,927.00
    Summary
    B-progenitor acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children. The genes Pax5 and Ikaros are frequently mutated in B-ALL, but how this contributes to leukaemia development and treatment resistance remains unclear. We have recently produced new B-ALL models driven by reversible suppression of Pax5 or Ikaros activity, and propose to use these models to uncover how these genes control leukaemia differentiation and regression.
    More information
    Funded Activity

    Mechanism Of Leukaemia Suppression By The Transcription Factor Ikaros

    Funder
    National Health and Medical Research Council
    Funding Amount
    $655,630.00
    Summary
    A subset of acute lymphoblastic leukaemias are characterised by mutations in the Ikaros gene. These leukaemias respond poorly to chemotherapy and require novel therapeutic approaches. We have discovered a new function of Ikaros in regulating leukaemia cell death. This project investigates how Ikaros regulates cell death and whether this is a general mechanism. Understanding Ikaros function is a step toward improved treatments for this aggressive type of leukaemia.
    More information
    Funded Activity

    Molecular Pathways Mediating The Anti-tumour Activity Of WIF1

    Funder
    National Health and Medical Research Council
    Funding Amount
    $462,342.00
    Summary
    Osteosarcoma is the most common bone cancer. Treatment often entails aggressive surgery with intensive chemotherapy, although one third of those diagnosed will still die from this disease. We have found that the molecule WIF1 can suppress osteosarcoma growth. In this project we aim to identify genetic modifiers of WIF1, potential WIF1 interactors and define active domains of WIF1 for the development of more effective targeted therapeutics for osteosarcoma.
    More information
    Funded Activity

    Defining The Role Of Reserve Stem Cells In Gastric Cancer

    Funder
    National Health and Medical Research Council
    Funding Amount
    $563,739.00
    Summary
    Over 800,000 deaths from stomach cancer occur annually. This often fatal disease is caused by chronic inflammation of the stomach lining. This proposal will investigate how stomach inflammation ‘reprograms’ a new type of 'cancer stem cell' to form tumours and evaluate ways to therapeutically target these cells to prevent disease. Collectively, these studies will inform new approaches for stomach cancer prevention and treatment.
    More information

    Showing 1-10 of 117 Funded Activites

    • 1
    • 2
    • 3
    • 4
    • 5
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback